Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Scherer, T., Sakamoto, K
doi:10.1093/geronj/11.3.298 3 Galvn I, et al
Compounders Question FDAs Rationale and Evidence Pointing to Safety Concerns On October 27, 2023, APC urged FDA via letter addressed to Gail Bormel, Director of the FDA's Office of Compounding Quality and Compliance, for transparency regarding the recent inclusion of substances into Category 2
Elevated SLC13A3 expression in tumor cells stabilizes PD-L1 through ITA-mediated posttranslational modification, promoting immune escape and resistance to checkpoint blockade
A 2018 study by Jain et al
US$ 25.81
US$ 26.17
US$ 21.16
US$ 23.76
US$ 22.58
US$ 27.33
US$ 22.07
US$ 27.22
US$ 26.76
